Hydrogen gas therapy induced shrinkage of metastatic gallbladder cancer: A case report

Duan-Ming Du, Feng Mu, Ji-Bing Chen, Ke-Cheng Xu, Wei Qian, Yang-Yang Ma, Zhong-Bao Pan

Read more:

DOI: 10.12998/wjcc.v7.i15.2065 DOI is the universal ID for this study.

This link will take you to the full study.


Background: We present the case of a 72-year-old female patient with gallbladder cancer (GBC) who developed in situ recurrence and liver metastases 9 mo after irreversible electroporation ablation and oral tegafur (a fluoropyrimidine derivative) chemotherapy, which failed to control the progression of the disease. The patient further developed metastases in the lymph nodes around the head of the pancreas. The patient had severe anemia, requiring weekly blood transfusions. The gallbladder tumor invaded the descending part of the duodenum, causing intestinal leakage and hepatic colonic adhesion. Case summary: The patient refused other treatments and began daily hydrogen inhalation therapy. After 1 mo of treatment, the gallbladder and liver tumors continued to progress, and intestinal obstruction occurred. After continuous hydrogen therapy and symptomatic treatments including gastrointestinal decompression and intravenous nutrition support, the intestinal obstruction was gradually relieved. Three months after hydrogen therapy, the metastases in the abdominal cavity gradually reduced in size, her anemia and hypoalbuminemia were corrected, lymphocyte and tumor marker levels returned to normal, and the patient was able to resume normal life.

Conclusion: This is the first report of an efficacy and safety study about hydrogen therapy in patient with metastatic GBC and a critical general condition, who has remained stable for more than 4 months.

Publish Year 2019
Country China
Rank Positive
Journal World Journal of Clinical Cases
Primary Topic Gallbladder
Secondary TopicCancer
Model Human
Tertiary TopicOncogenesis
Vehicle Gas
pH N/A
Application Inhalation